Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers

Proteomics

Volumn 11, Issue 12, 2011, Pages 2363-2376

  Ralhan, Ranju ^a,b,c   Masui, Olena ^a   Desouza, Leroi V ^a   Matta, Ajay ^a   Macha, Muzafar ^d   Siu, K W Michael ^a  

^a YORK UNIVERSITY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

1 D LC MS MS; Biomarkers; Cell biology; Head and neck cancer; Secretome; Secretory proteins

Indexed keywords

ALPHA ENOLASE; BIOLOGICAL MARKER; CYCLOPHILIN A; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; PEPTIDYLPROLYL ISOMERASE; SECRETORY PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA, CONDITIONED; EARLY DIAGNOSIS; HEAD AND NECK NEOPLASMS; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 79958124136     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000186     Document Type: Article

References (87)

1. McAllister, S. S., Weinberg, R. A., Tumor-host interactions: a far-reaching relationship. J. Clin. Oncol. 2010, 28, 4022-4028.
2. Liotta, L. A., Ferrari, M., Petricoin, E., Clinical proteomics: written in blood. Nature 2003, 425, 905.
3. Schaaij-Visser, T. B., Brakenhoff, R. H., Leemans, C. R., Heck, A. J. et al., Protein biomarker discovery for head and neck cancer. J. Proteomics 2010, 73, 1790-1803.
4. Pavlou, M. P., Diamandis, E. P., The cancer cell secretome: a good source for discovering biomarkers? J. Proteomics 2010, 73, 1896-1906.
5. Hu, S., Arellano, M., Boontheung, P., Wang, J. et al., Salivary proteomics for oral cancer biomarker discovery. Clin. Cancer Res. 2008, 14, 6246-6252.
6. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
7. Karagiannis, G. S., Pavlou, M. P., Diamandis, E. P., Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol. Oncol. 2010, 4, 496-510.
8. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
9. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
10. Gunawardana, C. G., Kuk, C., Smith, C. R., Batruch, I. et al., Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteome Res. 2009, 8, 4705-4713.
11. Planque, C., Kulasingam, V., Smith, C. R., Reckamp, K. et al., Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteomics 2009, 8, 2746-2758.
12. Sardana, G., Jung, K., Stephan, C., Diamandis, E. P., Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 2008, 7, 3329-3338.
13. Kulasingam, V., Diamandis, E. P., Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 2007, 6, 1997-2011.
14. Lawlor, K., Nazarian, A., Lacomis, L., Tempst, P., Villanueva, J., Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009, 8, 1489-1503.
15. Gourin, C. G., Zhi, W., Adam, B. L., Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope 2009, 119, 1291-1302.
16. Bijian, K., Mlynarek, A. M., Balys, R. L., Jie, S. et al., Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment (dagger). J. Proteome Res. 2009, 8, 2173-2185.
17. Allinen, M., Beroukhim, R., Cai, L., Brennan, C. et al., Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6, 17-32.
18. Chen, S. T., Pan, T. L., Juan, H. F., Chen, T. Y. et al., Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J. Proteome Res. 2008, 7, 1379-1387.
19. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics. 2010. CA Cancer J. Clin. 2010, 60, 277-300.
20. Ralhan, R., Desouza, L. V., Matta, A., Chandra Tripathi, S. et al., iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J. Proteome Res. 2009, 8, 300-309.
21. Ralhan, R., Desouza, L. V., Matta, A., Chandra Tripathi, S. et al., Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol. Cell. Proteomics 2008, 7, 1162-1173.
22. Weng, L. P., Wu, C. C., Hsu, B. L., Chi, L. M. et al., Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J. Proteome Res. 2008, 7, 3765-3775.
23. Vasko, V., Espinosa, A. V., Scouten, W., He, H. et al., Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA 2007, 104, 2803-2808.
24. Park, J. I., Strock, C. J., Ball, D. W., Nelkin, B. D., The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol. Cell Biol. 2003, 23, 543-554.
25. Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J. et al., The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63, 2172-2178.
26. Goldfinger, L. E., Stack, M. S., Jones, J. C., Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J. Cell Biol. 1998, 141, 255-265.
27. Ziober, A. F., Patel, K. R., Alawi, F., Gimotty, P. et al., Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin. Cancer Res. 2006, 12, 5960-5971.
28. Chen, L. C., Hsueh, C., Tsang, N. M., Liang, Y. et al., Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin. Cancer Res. 2008, 14, 3807-3813.
29. Sun, Y., Yi, H., Zhang, P. F., Li, M. Y. et al., Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett. 2007, 581, 131-139.
30. Leivo, I., Jee, K. J., Heikinheimo, K., Laine, M. et al., Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation. Cancer Genet. Cytogenet. 2005, 156, 104-113.
31. Wang, Z., Jiang, L., Huang, C., Li, Z. et al., Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol. Cell. Proteomics 2008, 7, 1639-1650.
32. Lo, W. Y., Tsai, M. H., Tsai, Y., Hua, C. H. et al., Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin. Chim. Acta 2007, 376, 101-107.
33. Koike, H., Uzawa, K., Nakashima, D., Shimada, K. et al., Identification of differentially expressed proteins in oral squamous cell carcinoma using a global proteomic approach. Int. J. Oncol. 2005, 27, 59-67.
34. He, Q. Y., Chen, J., Kung, H. F., Yuen, A. P., Chiu, J. F., Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4, 271-278.
35. Turhani, D., Krapfenbauer, K., Thurnher, D., Langen, H., Fountoulakis, M., Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 2006, 27, 1417-1423.
36. Celetti, A., Testa, D., Staibano, S., Merolla, F. et al., Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin. Cancer Res. 2005, 11, 8019-8027.
37. Chen, J., He, Q. Y., Yuen, A. P., Chiu, J. F., Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 2004, 4, 2465-2475.
38. Onda, M., Emi, M., Yoshida, A., Miyamoto, S. et al., Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr. Relat. Cancer 2004, 11, 843-854.
39. Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V. et al., The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69, 3021-3031.
40. Matta, A., Ralhan, R., DeSouza, L. V., Siu, K. W., Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom. Rev. 2010, 29, 945-961.
41. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 2009, 8, 1860-1877.
42. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
43. DeSouza, L. V., Taylor, A. M., Li, W., Minkoff, M. S. et al., Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J. Proteome Res. 2008, 7, 3525-3534.
44. DeSouza, L. V., Romaschin, A. D., Colgan, T. J., Siu, K. W., Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. Anal. Chem. 2009, 81, 3462-3470.
45. Kaur, J., Ralhan, R., Establishment and characterization of a cell line from smokeless tobacco associated oral squamous cell carcinoma. Oral Oncol. 2003, 39, 806-820.
46. Matta, A., DeSouza, L. V., Shukla, N. K., Gupta, S. D. et al., Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J. Proteome Res. 2008, 7, 2078-2087.
47. Li, H., DeSouza, L. V., Ghanny, S., Li, W. et al., Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry. J. Proteome Res. 2007, 6, 2615-2622.
48. Tang, W. H., Shilov, I. V., Seymour, S. L., Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res. 2008, 7, 3661-3667.
49. Bendtsen, J. D., Nielsen, H., von Heijne, G., Brunak, S., Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 2004, 340, 783-795.
50. Bendtsen, J. D., Jensen, L. J., Blom, N., Von Heijne, G., Brunak, S., Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 2004, 17, 349-356.
51. Tuck, M. K., Chan, D. W., Chia, D., Godwin, A. K. et al., Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 2009, 8, 113-117.
52. Kashat, L., So, A. K., Masui, O., Wang, X. S. et al., Secretome-based identification and characterization of potential biomarkers in thyroid cancer. J Proteome Res. 2010, 9, 5757-5769.
53. Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P. et al., Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001, 166, 7309-7318.
54. Wubbolts, R., Leckie, R. S., Veenhuizen, P. T., Schwarzmann, G. et al., Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J. Biol. Chem. 2003, 278, 10963-10972.
55. van Niel, G., Raposo, G., Candalh, C., Boussac, M. et al., Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001, 121, 337-349.
56. Skokos, D., Le Panse, S., Villa, I., Rousselle, J. C. et al., Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J. Immunol. 2001, 166, 868-876.
57. Admyre, C., Johansson, S. M., Qazi, K. R., Filen, J. J. et al., Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 2007, 179, 1969-1978.
58. Mears, R., Craven, R. A., Hanrahan, S., Totty, N. et al., Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 2004, 4, 4019-4031.
59. Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D. et al., Large-Scale Proteomics and Phosphoproteomics of Urinary Exosomes. J. Am. Soc. Nephrol. 2008, 20, 363-379.
60. Pisitkun, T., Shen, R. F., Knepper, M. A., Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 2004, 101, 13368-13373.
61. States, D. J., Omenn, G. S., Blackwell, T. W., Fermin, D. et al., Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 2006, 24, 333-338.
62. Wu, C. C., Hsu, C. W., Chen, C. D., Yu, C. J. et al., Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol. Cell. Proteomics 2010, 9, 1100-1117.
63. Piersma, S. R., Fiedler, U., Span, S., Lingnau, A. et al., Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res. 2010, 9, 1913-1922.
64. Pancholi, V., Multifunctional alpha-enolase: its role in diseases. Cell Mol. Life Sci. 2001, 58, 902-920.
65. van den Bemd, G. J., Krijgsveld, J., Luider, T. M., van Rijswijk, A. L. et al., Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol. Cell. Proteomics 2006, 5, 1830-1839.
66. Karnak, D., Beder, S., Kayacan, O., Ibis, E. et al., Neuron-specific enolase and lung cancer. Am. J. Clin. Oncol. 2005, 28, 586-590.
67. Tamesa, M. S., Kuramitsu, Y., Fujimoto, M., Maeda, N. et al., Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 2009, 30, 2168-2181.
68. Desmetz, C., Bascoul-Mollevi, C., Rochaix, P., Lamy, P.J. et al., Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin. Cancer Res. 2009, 15, 4733-4741.
69. Obchoei, S., Wongkhan, S., Wongkham, C., Li, M. et al., Cyclophilin A: potential functions and therapeutic target for human cancer. Med. Sci. Monit. 2009, 15, RA221-RA232.
70. Lee, J., Role of cyclophilin a during oncogenesis. Arch. Pharm. Res. 2010, 33, 181-187.
71. Huang, C. F., Sun, Z. J., Zhao, Y. F., Chen, X. M. et al., Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue. Oral Dis. 2011, 17, 328-343.
72. Arora, S., Matta, A., Shukla, N. K., Deo, S. V., Ralhan, R., Identification of differentially expressed genes in oral squamous cell carcinoma. Mol. Carcinog. 2005, 42, 97-108.
73. Matta, A., Bahadur, S., Duggal, R., Gupta, S. D., Ralhan, R., Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 2007, 7, 169.
74. Kobayashi, R., Deavers, M., Patenia, R., Rice-Stitt, T. et al., 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunol. Immunother. 2009, 58, 247-258.
75. He, Y., Wu, X., Liu, X., Yan, G., Xu, C., LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. J. Proteome Res. 2010, 9, 6180-6190
76. Morrison, D. K., The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009, 19, 16-23.
77. Badea, L., Herlea, V., Dima, S. O., Dumitrascu, T., Popescu, I., Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008, 55, 2016-2027.
78. Sewell, D. A., Yuan, C. X., Robertson, E., Proteomic signatures in laryngeal squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec. 2007, 69, 77-84.
79. Roesch-Ely, M., Nees, M., Karsai, S., Ruess, A. et al., Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007, 26, 54-64.
80. Matta, A., Tripathi, S. C., DeSouza, L. V., Grigull, J. et al., Heterogeneous ribonucleoprotein K (hnRNP K) is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int. J. Cancer 2009, 125, 1398-1406.
81. Jiang, P. Z., Gan, M., Huang, H., Shen, X. M. et al., Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells. Acta Biochim. Biophys. Sin. (Shanghai) 2005, 37, 97-106.
82. Barboro, P., Repaci, E., Rubagotti, A., Salvi, S. et al., Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br. J. Cancer 2009, 100, 1608-1616.
83. Roychoudhury, P., Chaudhuri, K., Evidence for heterogeneous nuclear ribonucleoprotein K overexpression in oral squamous cell carcinoma. Br. J. Cancer 2007, 97, 574-575.
84. Xiaofang, Y., Yue, Z., Xialian, X., Zhibin, Y. et al., Serum tumour markers in patients with chronic kidney disease. Scand. J. Clin. Lab Invest. 2007, 67, 661-667.
85. Culine, S., El Demery, M., Lamy, P. J., Iborra, F. et al., Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007, 178, 844-848.
86. Lenhard, M., Kuemper, C., Ditsch, N., Diebold, J. et al., Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours. Clin. Chem. Lab Med. 2007, 45, 657-661.
87. Vos, M. J., Postma, T. J., Martens, F., Uitdehaag, B. M. et al., Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res. 2004, 24, 2511-2514.